An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information
From MaRDI portal
Publication:6630315
DOI10.1002/sim.9980zbMATH Open1548.62484MaRDI QIDQ6630315
Publication date: 31 October 2024
Published in: Statistics in Medicine (Search for Journal in Brave)
pharmacokineticspharmacodynamicsmaximum tolerated dosedose findingcytokine release syndromedose-toxicity curve
Cites Work
- Continual Reassessment Method: A Practical Design for Phase 1 Clinical Trials in Cancer
- Inference from iterative simulation using multiple sequences
- Accelerating MCMC via Kriging-based adaptive independent proposals and delayed rejection
- Dynamic calibration of pharmacokinetic parameters in dose-finding studies
- Easy-to-implement Bayesian methods for dose-escalation studies in healthy volunteers
- Dose‐finding methods for Phase I clinical trials using pharmacokinetics in small populations
- Bayesian dose regimen assessment in early phase oncology incorporating pharmacokinetics and pharmacodynamics
- Using simulation studies to evaluate statistical methods
- Bayesian modeling of a bivariate toxicity outcome for early phase oncology trials evaluating dose regimens
- A Bayesian time-to-event pharmacokinetic model for phase I dose-escalation trials with multiple schedules
This page was built for publication: An extended Bayesian semi-mechanistic dose-finding design for phase I oncology trials using pharmacokinetic and pharmacodynamic information